Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
NCT04979585 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66
Last updated 2021-08-03
Summary
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.
Conditions
Interventions
- DRUG
-
Camrelizumab
200mg ,IV,d1,Q3W.
- DRUG
-
8mg,oral, d1-14,Q3W.
- DRUG
-
260mg/m2,IV,d1,Q3W.
Sponsors & Collaborators
-
Di Wu
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-15
- Primary Completion
- 2023-04-14
- Completion
- 2023-08-14
Countries
- China
Study Locations
More Related Trials
-
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
NCT06327698 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
NCT03448497 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
NCT04653038 ·Status: TERMINATED ·Phase: PHASE1
-
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
NCT05928962 ·Status: UNKNOWN ·Phase: PHASE1
-
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT04472806 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
NCT04884997 ·Status: UNKNOWN ·Phase: PHASE2
-
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272 ·Status: ACTIVE_NOT_RECRUITING
-
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
NCT05106023 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106 ·Status: RECRUITING ·Phase: PHASE3
-
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.
NCT03602547 ·Status: UNKNOWN ·Phase: PHASE2
-
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
NCT04072900 ·Status: UNKNOWN ·Phase: PHASE1
-
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
NCT05104801 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
NCT04331093 ·Status: RECRUITING ·Phase: PHASE2
-
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT04091217 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
NCT07280832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
NCT04017897 ·Status: UNKNOWN ·Phase: PHASE2
-
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
NCT05827770 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00729950 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
NCT02110355 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma
NCT03941795 ·Status: UNKNOWN ·Phase: PHASE2
-
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
NCT05512481 ·Status: RECRUITING ·Phase: PHASE2
-
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
NCT04462965 ·Status: UNKNOWN ·Phase: PHASE2
-
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
NCT05664139 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
NCT03454919 ·Status: UNKNOWN ·Phase: PHASE2